Background: Treatment with anti-epileptic drugs (AEDs) in high-grade glioma (HGG) patients is met with various side-effects, such as cognitive deterioration. The cognitive effects of both older and newer AEDs in HGG patients are largely unknown. The aim of this study is to determine the effect of older and newer AEDs on cognitive performance in postoperative HGG patients. Methods: We selected HGG patients using older, newer or no AEDs from 3 separate cohorts, as they represented distinct treatment era and provided the opportunity to compare older and newer AEDs. In all three cohorts, patients were included within six weeks following neurosurgery before the start of postoperative treatment. Cognitive functioning evaluated by an extensive neuropsychological assessment, executed in six cognitive domains (attention, executive functioning, verbal memory, working memory, psychomotor functioning, and information processing speed). Results: 117 patients met the inclusion criteria; 44 patients used no AED, 35 were on monotherapy with a newer AED (all levetiracetam), and 38 on monotherapy with an older AED (valproic acid or phenytoin). Both patients on older and newer AED performed equal to patients not on AED, and patients on levetiracetam performed even better on verbal memory tests than patients not on AED. Post-hoc analyses revealed that within the group of patients using older AEDs, patients on valproic acid performed better than patients on phenytoin. Conclusions: Both levetiracetam and valproic acid were not associated with additional cognitive deficits in HGG patients. Both AED even appeared to have a beneficial effect on verbal memory in these patients.
Introduction
High-grade gliomas (HGG; WHO grade III and IV) are the most common and most malignant primary brain tumors, with a median overall survival of 15 to 24 months. 13 The incidence of epilepsy in HGG is 30 to 50%. 13;393;394 Seizures have a considerable negative impact on quality of life. Treatment of epilepsy with anti-epileptic drugs (AEDs) in this patient group is difficult due to pharmacokinetic interactions, over-expression of multi-drug transporters in tumor tissue and tumor vasculature resulting in pharmacoresistance, and increased vulnerability to side-effects, such as skin rashes, somnolence, weight loss, but most of all cognitive deficits. 61;64 Particularly older AEDs are thought to negatively influence cognitive functioning. 395 The most commonly affected cognitive domains are attention, psychomotor speed, and memory. 396 Also without AED treatment, glioma patients have impaired cognition in comparison to age-and education-matched healthy individuals and to other cancer patients. 21 This is due to the tumor itself, 22 but also to various anti-tumor treatments. 61 Thus, as glioma patients may already have impaired cognitive functioning, it is very important to avoid additional cognitive side-effects related to AED use. A considerable number of studies in non-tumor populations reported deleterious effects of particularly older AEDs on cognition in general (see review 61;64 ), while newer AEDs might not have such deleterious cognitive impact. 26 We have previously shown negative effects of older AEDs on cognitive functioning in low-grade glioma patients (WHO grade II). 382;383;389;397 Levetiracetam (a newer AED) has been reported not to lead to significant cognitive side-effects in epilepsy patients, potentially even enhancing performance in some cognitive domains. 396 It remains to be determined, however, to what extent AEDs affect cognitive functioning in HGG patients. Since high-grade glioma patients already have impaired cognitive functioning due to their tumor, one might hypothesize that the impact of cognitive side-effects of AEDs is likely to be more prominent in glioma patients. Owing to the vast array of AEDs with comparable efficacy, the cognitive side-effect profile of these drugs may become increasingly crucial when choosing an AED.
Based on previous literature, we hypothesize that (1) HGG patients using a newer AED (levetiracetam) perform similar on cognitive tests as patients not using AEDs, that (2) HGG patients on levetiracetam show better cognitive performance than patients using older AEDS (valproic acid, phenytoin), and that (3) HGG patients using valproic acid or phenytoin are more cognitively impaired than patients not using AEDs. In order to investigate these hypotheses, we assessed the effect of levetiracetam, valproic acid, and phenytoin monotherapy on cognitive functioning in HGG patients.
Methods

Patients
We selected patients with HGG from three prospective cohort studies (see figure 1) , that were performed at several tertiary referral centres for brain tumor patients in The Netherlands. We included these cohorts representing two distinct treatment eras in order to compare older AEDs with the newer AED levetiracetam. In all three cohorts, patients were included at the time of initial diagnosis following neurosurgical intervention. Cohort 1 comprised of HGG patients who were recruited between June 2007 and October 2010, all using levetiracetam. Cohort 2 consisted of newly-diagnosed HGG patients who were recruited between February 1997 and June 1999, all of whom used older AEDs or no AEDs. Quality of life and cognition in this cohort have been reported previously.
17 Cohort 3 comprised of newly-diagnosed glioblastoma multiforme (GBM) patients who were included between March 2005 and October 2010, who used levetiracetam, older AEDs, or had no AED treatment. Cognitive performance of 13 patients in this cohort has been described in a study investigating cognition during the currently standard therapy of radiotherapy plus concomitant and adjuvant temozolomide.
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In all cohorts, the following inclusion criteria were applied: (1) histopathologically confirmed HGG (i.e. WHO grade III astrocytoma, oligodendroglioma, or oligoastrocytoma and WHO grade IV glioblastoma multiforme), (2) no previous irradiation or chemotherapy, (3) age > 18 years, and (4) ability to communicate in the Dutch language. In cohort 3, only patients with a GBM diagnosis were included. In cohort 1, an extra inclusion criterion was levetiracetam monotherapy. All patients were included directly after neurosurgical intervention (either biopsy or tumor resection). They underwent neuropsychological testing within 6 weeks after neurosurgery and before start of other anti-tumor treatment (i.e. chemotherapy and/or radiotherapy). Various clinical parameters were recorded, such as performance status (Karnofsky Performance Status Scale 387 ), type of neurosurgery (biopsy or resection), and histopathological diagnosis. Furthermore, AED use, AED type, and corticosteroid use were registered. All three studies received approval from the ethics committees of the participating hospitals and all patients gave written informed consent prior to the day of testing.
Neuropsychological assessment
Identical neuropsychological assessments were administered in all cohorts by a trained psychometrician under supervision of a board-certified clinical neuropsychologist [MK] , and comprised of the letter-digit substitution test, concept shifting test, Stroop colour-word test, visual verbal learning test, memory comparison test, and categoric word fluency (see table 1 ). The total time required to complete the assessment was approximately 60 minutes. Patients' scores on each subtest were compared to the scores of a group of healthy controls that have been described previously, 26 matched for age, sex, and educational level. Individual patients' test scores were converted to z-scores using the mean and standard deviation of the matched control group. In order to explore different aspects of cognition, the z-scores were also summarized into six cognitive domains, namely (1) attention, (2) executive functioning, (3) verbal memory, (4) working memory, (5) psychomotor functioning, and (6) information processing speed. Construction of these domains has been reported previously, 22 and was based on a Principal Component Analysis using Varimax rotation with Kaiser normalization performed on the z-scores of a large group of healthy controls. 26 These domains are commonly used in clinical practice and research.
Statistical analyses
All statistical analyses were performed using SPSS 15.0 for Windows. Differences in patient characteristics between the different groups (no AEDs, older AEDs, levetiracetam) were tested by means of Fisher's exact tests (sex, histopathological diagnosis, tumor lateralization, type of surgery) or Student's t-tests (age, performance status). In order to test our first hypothesis that patients on levetiracetam did not perform poorer than patients not using AEDs, backward linear regression analyses were performed with the different cognitive domains as dependent variables and levetiracetam use versus no AED use as predicting categorical variable. The second hypothesis, that levetiracetam is related to better cognitive performance when compared to valproic acid and phenytoin, was tested in similar regression analyses, now using levetiracetam versus the other AEDs as the predictor. Finally, the third hypothesis, which concerns poorer cognition in patients using valproic acid or phenytoin as compared to patients not on AED treatment, was investigated using older AED use versus no AED use as the predicting variable. In addition, clinical variables that significantly differed between patient cohorts (in this case only Karnofsky performance status) were entered in the regression model. The significance level for all these regression analyses was set at p<0·05, but because multiple tests were performed (per cognitive domain), the significance level of the regression model was set to p<0·008 (according to Bonferroni's correction). Figure 1 shows the flowchart of patients per cohort. Initially, 133 patients were included in these cohorts. However, 15 of 133 patients had to be excluded, due to inability to finish the neuropsychological assessment, inadequate documentation of AED use, or use of AED polytherapy. Furthermore, only one patient used carbamazepine, which prompted us to remove this patient from the analyses. Therefore, 117 patients were included in the analyses (see table 2 for patient characteristics). The three cohorts did not differ with respect to age, sex, type of surgery, dexamethasone use, and tumor lateralisation. However, cohort 3 had significantly lower performance status as expressed by Karnofsky scores (median=80, range=30-100) than cohorts 1 (median=90, range 70-100) and 2 (median=90, range=60-100).
Results
Patient characteristics
Patients not using AEDs, patients using levetiracetam, and patients using phenytoin or valproic acid did not differ significantly with respect to age, sex, type of surgery, tumor grade, tumor lateralization, and dexamethasone use. However, patients using levetiracetam had a significantly better performance status (median=90, range 70-100) than patients not using AEDs (median=80 range 40-100) and patients on older AEDs (median=80, range 30-100). Because of the difference in performance status between groups, performance status was used as a covariate in subsequent analyses. 
Cognitive effects of newer and older AEDs
Our first hypothesis, that levetiracetam use was not associated with poorer cognitive functioning than using no AEDs, was confirmed. Notably, patients on levetiracetam even performed significantly better (M=-0·07, SD=1·04) than patients not using AEDs (M=-0·73, SD=1·05) with respect to verbal memory (see table 3), regardless of Karnofsky performance status (which was also a significant predictor). Although there were no significant differences between groups in terms of tumor location (i.e. frontal, temporal, occipital, or parietal) or lateralization (i.e. left, right, or bilateral), we subsequently entered these variables in the same backward regression analysis (verbal memory as dependent, levetiracetam versus no AED use and tumor location/lateralization as predictors) to ensure our results were not due to tumor location or lateralization. Results show that although tumor lateralization in the left hemisphere is related to poorer verbal memory (Beta = -.306, p=.005), the use of levetiracetam is still significantly related to better verbal memory performance (Beta = .320, p=.003) in the same model. Tumor location was not significantly related to verbal memory in this analysis.
We performed post-hoc analyses to further explore which aspects of verbal memory were positively influenced by levetiracetam use when compared to patients not using AEDs, as the test used for verbal memory assesses different aspects of memory and may further elucidate the reported differences in memory functioning. Cognitive z-scores per subtest were compared bymeans of Student's t-tests, showing significantly higher scores in the levetiracetam group on the , maximum number of words remembered during the five trials (t(76)=-3·63, p=·001), and total number of words remembered during the encoding phase (t(76)=-2·85, p=·007). All three of these sub-scores indicate better encoding, storage and active retrieval in patients using levetiracetam. This effect can be seen in figure 2 , in which the number of words remembered over all five trials and during delayed recall and recognition per group are plotted. We found a trend towards a better performance of patients using levetiracetam compared with non-AED users regarding the active retrieval of information 20 minutes following encoding (t(75)=-1·71, p=·091). There were no significant differences in recognition of the words, indicating that passive retrieval was not positively influenced by levetiracetam use. Our second hypothesis was not confirmed: there were no significant cognitive differences between patients using levetiracetam and patients using older AEDs (phenytoin and valproic acid). Furthermore, patients on older AEDs did not perform poorer than patients not using AEDs, hereby invalidating the third hypothesis. These results were unchanged when taking tumor location and lateralization into account 
Post-hoc analyses: valproic acid and phenytoin
Because there were no significant differences in cognitive functioning between older AEDs and the two other groups, post-hoc analyses were performed in order to explore whether this could be due to differences between the two older AEDs (valproic acid and phenytoin) when compared to the other groups separately (see figure 3) . Backward regression analyses (with performance status as a covariate) were performed, investigating cognitive differences between all individual AED groups (no AEDs, levetiracetam, valproic acid, phenytoin). Interestingly, these analyses revealed that patients on valproic acid performed better (M=-0·20, SD=0·93) in the domain of verbal memory than patients not using AEDs (M=-0·73, SD=1·05; see table 4). This difference was again mainly due to differences in the encoding phase of the visual verbal learning test, as patients on valproic acid performed better with respect to verbal recall after the first trial (t(62)=-2·28, mainly due to differences in the encoding phase of the visual verbal learning test, as patients on valproic acid performed better with respect to verbal recall after the first trial (t(62)=-2·28. Furthermore, patients using levetiracetam were superior (M=-0·93, SD=1·09) to patients using phenytoin (M=-1·97, SD=2·32) in their working memory capacity (see table 4 ). There were no significant differences between other AED groups. 
Discussion
We evaluated the effect of phenytoin, valproic acid and levetiracetam on cognitive functioning in HGG patients. We confirmed our first hypothesis that the use of levetiracetam is not associated with additional cognitive deficits; patients on levetiracetam performed equal to patients not using AEDs, and even performed better regarding encoding and memorization of verbal information. Although patients with left-sided tumors as a group performed poorer in the domain of verbal memory, these results with respect to levetiracetam remained significant when controlling for tumor location and lateralization. We could not confirm our second and third hypotheses; patients on levetiracetam did not perform superior to patients on older AEDs (phenytoin, valproic acid), and patients on older AEDs did not perform worse than non-AED users. We performed post-hoc analyses in order to explore whether this could be due to differences between the two older AEDs (valproic acid and phenytoin). Results indicate that the positive effect of valproic acid on verbal memory probably outbalanced the negative impact of phenytoin on cognition. Klein and colleagues found that low-grade glioma (LGG) patients on AEDs performed poorer on cognitive tasks pertaining to information processing, psychomotor function, attention, working memory, and executive function, than those without AEDs. 26 The differences between the present study and these earlier findings might be explained by the type of drugs used: all epileptic patients in the study of Klein et al. 61 used older AEDs (carbamazepine, valproic acid, phenytoin, and phenobarbital), and no separate analyses regarding different types of AEDs were performed. In line with this, studies comparing effects of different AEDs on cognition in non tumor-related epilepsy patients also report higher risk of cognitive impairment when using older AEDs (see review 61 ). Adverse effects with respect to attention, motor speed, and memory are similar when comparing older AEDs (phenytoin, carbamazepine, and valproic acid).
37
Our results indicate better verbal memory in patients using levetiracetam monotherapy compared to patients not using AEDs. A previous longitudinal study evaluating 29 brain tumor patients on levetiracetam monotherapy reported significant decreases in MMSE score, suggesting that cognitive functioning deteriorated. 19 However, it is well-known that the MMSE is limited in assessing multiple aspects of cognitive function, as opposed to the more extensive cognitive battery applied in our study. 389 Furthermore, the patient population in the former study was heterogeneous (e.g. meningeoma, glioma, hemangiopericytoma). Corroborating our results, one study evaluated 293 non tumor-related epilepsy patients on levetiracetam treatment, 380;381;384;392;398 particularly when compared to other AEDs. 61;64;399;400 In addition to levetiracetam, other newer AEDs such as oxcarbazepine and lamotrigine report relatively few cognitive impact in the epilepsy population. 64 We also report beneficial effects of valproic acid on verbal memory, although these results were obtained in post-hoc analyses and must thus be interpreted with caution. Previous reports on the effect of valproic acid on cognition are highly ambiguous. A number of studies in rats and humans have shown valproic acid to be associated with cognitive improvement (alertness, attention, immediate recall), 61 but the majority of studies report modest deterioration.
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The mechanisms by which AEDs influence cognitive function are still the subject of research. One may expect that AEDs improve cognitive function by decreasing seizure burden. However, amply described cognitive deficits due to AED treatment, both in patients who are seizure-free as well as patients who are not, contradict this explanation. 64 The effects that AEDs exert on cognition are probably explained by their influence on receptors, inhibitory-and excitatory neurotransmitters, and ion-channels. 121 Negative effects on cognitive functioning are mainly attributed to sodium blockade, increased GABA-activity, and a decreased glutamate activity. Several studies suggest that functioning of various receptors and ion-channels is altered in glioma tissue, which could contribute to cognitive deficits. 64 Newer AEDs, such as levetiracetam, may affect the altered receptor and ion-channels in glioma tissue and thereby improve cognitive function. Based on our findings regarding verbal memory in patients using levetiracetam, we may speculate that levetiracetam specifically promotes processes that enhance efficient storage of information. Positive effects on cognition of AEDs are attributed to inhibition of calcium-mediated cellular function (e.g. phosphorylation, neurotransmitter release), reduction of glutamate release from presynaptic terminals, and psychotropic effects. 174 Levetiracetam has a distinct mechanism of action which possibly contributes to these positive effects. It binds to the synaptic vesicle protein (SV2A) and is believed to restore the function of SV2A. Dysfunction of SV2A leads to calcium accumulation during repeated action potential generation. 75 Therefore, restoring the function of SV2A results in inhibition of calcium mediated cellular function. Furthermore, levetiracetam reduces neuronal necrosis and is suggested to have a protective effect on astrocytes, 401 which could contribute to a positive effect on cognition as a recent study demonstrated that astrocytes play an important role in the formation and maintenance of long-term memories. 402 In addition, it has been suggested that levetiracetam might influence the metabolism of attention and the language area.
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In addition, it would be interesting to elaborate these results to other patients populations with impaired memory such as Alzheimer disease (AD) of mild incognitive impairment (MCI). As the neural substrates differ between brain tumor patients and AD/MCI patients, results in HGG patients cannot be extrapolated to other patient groups with cognitive deficits. There is some evidence however that effects are similar in AD patients. Cumbo et a. 404 investigated the effect of levetiracetam, lamotrigine and phenobarbital in 95 patients with epilepsy and Alzheimer's disease Corroborating our results, they found that levetiracetam was associated with improved cognitive performance, specifically regarding attention level and oral fluency items. Dolder et al. 405;406 . recently reviewed literature regarding anticonvulsants as a possible treatment in demented patients with behavioral disturbances, taking cognitive treatment also in consideration. They concluded that levetiracetam might have a role in the treatment of behavioral symptoms in dementia and that it appears to have less deleterious effects on cognition than some other anticonvulsants, but study limitations substantially hampered the strength of such a recommendation. Although these studies also suggest that levetiracetam may add value in patients with impaired memory such as MCI or AD, more extensive efforts in this research area are required to address this issue and provide more definitive answers.
Our study consists of a homogeneous population of HGG patients and all patients underwent a complete neuropsychological assessment after neurosurgery and before adjuvant treatment. This standardized procedure permitted a reliable evaluation of the effect of AED on cognitive functioning in HGG patients. However, this study has some limitations. First, since the patients are not randomized in treatment groups, bias regarding choice of medical anti-epileptic treatment could exist. Physicians choose AEDs by determining seizure type and burden, patient characteristics (e.g. ability to comply with complex treatment schemes) and evidently financial aspects. However, apart from performance status, we found no statistically significant differences between relevant clinical characteristics. Performance status was therefore entered as a covariate in all analyses. Furthermore, different cohorts were used, which may have induced some form of bias. However, the study protocols in the three cohorts were identical, and there were no significant differences in clinical characteristics (except performance status, for which we corrected our analyses). Third, we did not register seizure burden, dosage range and AED serum levels. Although different dosages may be related to cognitive performance within a patient group using a particular AED, our group-level analyses are likely to minimize the effect of dosage on cognition: all groups will likely contain a comparable dosage range of that particular AED. In addition, the dispersal in dosage range and serum levels by which individual patients are confronted with side-effects, such as poor cognition, is large and variable. 13;26;27 This makes it impossible to determine whether dosage range or serum levels affect cognition. Furthermore, comparing dosage between different AEDs poses a problem in itself.
In conclusion, our results indicate that levetiracetam does not induce additional cognitive deficits in HGG patients and even improves verbal memory function. Valproic acid also seems to improve verbal memory, while phenytoin in particular is harmful to cognition in these patients. Our findings provide arguments to consider prescribing either levetiracetam or valproic acid to epileptic HGG patients, especially those who have memory complaints. Well-designed controlled studies in brain tumor patients and non brain-tumor patients are needed to further address the potential positive influence on cognition of AEDs.
